Merck & Co., Inc. (MRK)
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE
Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.
Dividend Yield Theory Says Merck Is A Buy
Dividend Yield Theory identifies Merck & Co., Inc. as undervalued, with a 4.09% yield well above its historical mean, suggesting strong total return potential. Despite Keytruda's looming patent expiration and political headwinds, Merck's robust pipeline and adaptability offer a credible path to future growth. DYT analysis projects a 42%-83% total return over four years, with Merck meeting or exceeding most fundamental quality metrics.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit in Dubai
DUBAI, United Arab Emirates--(BUSINESS WIRE)-- #CEO--Merck Foundation conducted the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit 2025 in Dubai, United Arab Emirates.
Merck: Don't Let Today's Bargain Opportunity Pass You By
Merck: Don't Let Today's Bargain Opportunity Pass You By
Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)
Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant share price pullback, now trading at just 10x adjusted earnings and offering a 4% dividend yield. Despite expensive M&A and some new product launches, non-Keytruda sales remain flat, highlighting the urgent need for diversification.
40% Upside For Merck Stock?
Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its pipeline. Earlier this month, we highlighted how Keytruda is a ticking time bomb for Merck stock.
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
Merck (MRK) closed the most recent trading day at $78.83, moving 1.05% from the previous trading session.
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.
Merck Moves Past 50-Day Average: How to Play MRK Stock Now
MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.
MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal
Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.
Why the Market Dipped But Merck (MRK) Gained Today
Merck (MRK) closed at $79.29 in the latest trading session, marking a +1.29% move from the prior day.
